Who's the Boss? Merck Names Managerial Team As Schering Merger Looms
Executive Summary
In a long-awaited move, Merck announced a managerial reorganization, placing several Schering-Plough executives in top management spots once the two companies finalize their proposed $41 billion merger later this year
You may also be interested in...
Will Saunders Bring Transformation To Forest?
The specialty pharma long has been scrutinized for its decisions regarding the patent cliff and business development. Now, a new CEO will have the chance to keep the company on its current course or mirror the transformations he’s put in motion at other companies.
Merck Vaccine President Slot Opens Up With McGlynn's Retirement
A consummate Merck insider, Margie McGlynn, announces her plans to retire, as the company prepares for its pending merger with Schering-Plough.
J&J To Seek Remicade Rights Amid Pending Schering-Plough/Merck Merger
Merck and Schering argue the merger does not constitute “change of control” for Remicade and Simponi under initial J&J agreement.